Entrada Therapeutics, Inc. - Common Stock, par value $0.0001 per share (TRDA)

Q: What does CUSIP 29384C108 represent in this 13F holders report?

CUSIP 29384C108 is the security identifier for TRDA - Entrada Therapeutics, Inc. - Common Stock, par value $0.0001 per share used to aggregate holder disclosures.

Q: How many institutions held TRDA - Entrada Therapeutics, Inc. - Common Stock, par value $0.0001 per share in Q1 2025?

110 institutional investors reported TRDA - Entrada Therapeutics, Inc. - Common Stock, par value $0.0001 per share for Q1 2025. Use the holders table for investor-level position and value details.

CUSIP: 29384C108

Q1 2025 13F Holders as of 31 Mar 2025

Type / Class: Equity / Common Stock, par value $0.0001 per share
Shares outstanding: 38,346,880
Total 13F shares: 30,241,830
Share change: -404,398
Total reported value: $274,509,238
Put/Call ratio: 28%
Price per share: $9.04
Number of holders: 110
Value change: -$4,478,805
Number of buys: 45
Number of sells: 53

Quarterly Holders Quick Answers

What is CUSIP 29384C108?
CUSIP 29384C108 identifies TRDA - Entrada Therapeutics, Inc. - Common Stock, par value $0.0001 per share in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Next holder-history checks

These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.

Back to full security ownership history for the broader multi-quarter picture.
Latest 13F filings for newly reported positions across managers.
Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
SEC investors directory for manager drilldown.

Explore More Reporting Periods

Jump to adjacent filing periods for faster comparison and easier crawl discovery.

Newer quarter: Q2 2025
Previous quarter: Q4 2024

Recent filing periods for CUSIP 29384C108:

Q1 2026 Q4 2025 Q3 2025 Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024

Top shareholders of TRDA - Entrada Therapeutics, Inc. - Common Stock, par value $0.0001 per share (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.

Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

Holder	Source	Role / Reporting	Ownership %	Shares	Holdings Value	12M Net Δ	As of	Details
MPM BioVentures 2014, L.P.	3/4/5	10%+ Owner	— class O/S missing	4,381,062	$88,628,884	—	10 Dec 2024	3/4/5
MPM BIOVENTURES 2018, L.P.	3/4/5	10%+ Owner	— class O/S missing	4,381,062	$88,628,884	—	10 Dec 2024	3/4/5
BAKER BROS. ADVISORS LP	13F	Company	13%	4,865,819	$84,130,011	—	31 Dec 2024	13F
5AM Venture Management, LLC	13F	Company	11%	4,408,379	$76,220,873	—	31 Dec 2024	13F
MPM ASSET MANAGEMENT LLC	13F	Company	11%	4,381,062	$75,748,562	—	31 Dec 2024	13F
PRICE T ROWE ASSOCIATES INC /MD/	13F	Company	7.6%	2,903,025	$50,194,000	—	31 Dec 2024	13F
ROCHE HOLDING LTD	3/4/5	10%+ Owner	— class O/S missing	2,813,525	$44,988,265	—	02 Nov 2021	3/4/5
JANUS HENDERSON GROUP PLC	13F	Company	5.4%	2,080,367	$36,011,152	—	31 Dec 2024	13F
BlackRock, Inc.	13F 13D/G	Company	5.3% from 13D/G	1,974,452	$34,138,275	—	31 Dec 2024	13F 13D/G
Redmile Group, LLC	3/4/5	10%+ Owner	— class O/S missing	1,954,420	$31,251,176	—	02 Nov 2021	3/4/5
VANGUARD GROUP INC	13F	Company	3.8%	1,464,237	$25,316,657	—	31 Dec 2024	13F
FMR LLC	13F	Company	3.7%	1,399,916	$24,204,548	—	31 Dec 2024	13F
ROCHE FINANCE LTD	13D/G	—	6.9%	2,569,115	$23,019,270	$0	31 Dec 2024	13D/G
WELLINGTON MANAGEMENT GROUP LLP	13F	Company	2.7%	1,031,826	$17,840,271	—	31 Dec 2024	13F
StepStone Group LP	13F	Company	2%	761,277	$13,162,479	—	31 Dec 2024	13F
TCG Crossover Management, LLC	13F	Company	1.5%	584,955	$10,113,872	—	31 Dec 2024	13F
GEODE CAPITAL MANAGEMENT, LLC	13F	Company	1.5%	573,891	$9,925,236	—	31 Dec 2024	13F
STATE STREET CORP	13F	Company	1.3%	504,979	$8,731,087	—	31 Dec 2024	13F
NORTHERN TRUST CORP	13F	Company	0.83%	318,177	$5,501,281	—	31 Dec 2024	13F
GOLDMAN SACHS GROUP INC	13F	Company	0.74%	285,272	$4,932,357	—	31 Dec 2024	13F
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP	13F	Company	0.58%	222,520	$3,847,371	—	31 Dec 2024	13F
DIMENSIONAL FUND ADVISORS LP	13F	Company	0.57%	217,006	$3,752,155	—	31 Dec 2024	13F
JACOBS LEVY EQUITY MANAGEMENT, INC	13F	Company	0.55%	212,717	$3,677,877	—	31 Dec 2024	13F
CHARLES SCHWAB INVESTMENT MANAGEMENT INC	13F	Company	0.51%	197,127	$3,408,326	—	31 Dec 2024	13F
RENAISSANCE TECHNOLOGIES LLC	13F	Company	0.43%	166,200	$2,873,598	—	31 Dec 2024	13F
MOORE CAPITAL MANAGEMENT, LP	13F	Company	0.27%	105,000	$1,815,450	—	31 Dec 2024	13F
Bank of New York Mellon Corp	13F	Company	0.26%	101,358	$1,752,480	—	31 Dec 2024	13F
FEDERATED HERMES, INC.	13F	Company	0.26%	99,814	$1,725,784	—	31 Dec 2024	13F
Nuveen Asset Management, LLC	13F	Company	0.23%	87,506	$1,512,979	—	31 Dec 2024	13F
Connor, Clark & Lunn Investment Management Ltd.	13F	Company	0.22%	85,621	$1,480,387	—	31 Dec 2024	13F
MORGAN STANLEY	13F	Company	0.21%	81,873	$1,415,584	—	31 Dec 2024	13F
FIRST TRUST ADVISORS LP	13F	Company	0.19%	73,749	$1,275,120	—	31 Dec 2024	13F
CITADEL ADVISORS LLC	13F	Company	0.18%	70,669	$1,221,867	—	31 Dec 2024	13F
MASSACHUSETTS FINANCIAL SERVICES CO /MA/	13F	Company	0.18%	67,384	$1,165,069	—	31 Dec 2024	13F
AMERICAN CENTURY COMPANIES INC	13F	Company	0.16%	59,710	$1,032,386	—	31 Dec 2024	13F
MANUFACTURERS LIFE INSURANCE COMPANY, THE	13F	Company	0.15%	56,557	$977,871	—	31 Dec 2024	13F
LAZARD ASSET MANAGEMENT LLC	13F	Company	0.14%	55,517	$959,000	—	31 Dec 2024	13F
LPL Financial LLC	13F	Company	0.14%	55,154	$953,613	—	31 Dec 2024	13F
AQR CAPITAL MANAGEMENT LLC	13F	Company	0.14%	54,979	$950,587	—	31 Dec 2024	13F
UBS Group AG	13F	Company	0.14%	53,091	$917,943	—	31 Dec 2024	13F
ACADIAN ASSET MANAGEMENT LLC	13F	Company	0.13%	51,491	$890,000	—	31 Dec 2024	13F
BARCLAYS PLC	13F	Company	0.13%	51,365	$888,101	—	31 Dec 2024	13F
Nan Fung Group Holdings Ltd	13F	Company	0.13%	49,082	$848,628	—	31 Dec 2024	13F
TD ASSET MANAGEMENT INC	13F	Company	0.12%	47,788	$826,255	—	31 Dec 2024	13F
AMERIPRISE FINANCIAL INC	13F	Company	0.11%	40,624	$702,389	—	31 Dec 2024	13F
MARTINGALE ASSET MANAGEMENT L P	13F	Company	0.1%	38,623	$667,793	—	31 Dec 2024	13F
Nerissa Kreher	3/4/5	Chief Medical Officer	— mixed-class rows	61,537 mixed-class rows	$640,192	—	01 Sep 2023	3/4/5
RHUMBLINE ADVISERS	13F	Company	0.1%	36,731	$635,069	—	31 Dec 2024	13F
UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC	13F	Company	0.09%	35,750	$618,118	—	31 Dec 2024	13F
BANK OF AMERICA CORP /DE/	13F	Company	0.09%	35,721	$617,616	—	31 Dec 2024	13F

Institutional Holders of Entrada Therapeutics, Inc. - Common Stock, par value $0.0001 per share (TRDA) as of Q1 2025

As of 31 Mar 2025, Entrada Therapeutics, Inc. - Common Stock, par value $0.0001 per share (TRDA) was held by 110 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 30,241,830 shares. The largest 10 holders included BAKER BROS. ADVISORS LP, 5AM Venture Management, LLC, MPM ASSET MANAGEMENT LLC, PRICE T ROWE ASSOCIATES INC /MD/, JANUS HENDERSON GROUP PLC, BlackRock, Inc., VANGUARD GROUP INC, FMR LLC, WELLINGTON MANAGEMENT GROUP LLP, and StepStone Group LP. This page lists 110 institutional shareholders reporting positions in this security for the Q1 2025 filing period.

Investor	Option	Weight %	Change %	Value $	* Price	Shares	Share Change	Activity	Report Period

Compare Q1 2025 vs Q4 2024 Across Filers

Q4 2024 holders

102

Q1 2025 holders

110

Holder diff

Investor	Q4 2024 Shares	Q1 2025 Shares	Share Diff	Share Chg %	Q4 2024 Value $	Q1 2025 Value $	Value Diff $	Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend

Quarterly Value Trend

Quarterly Shares Trend

* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.